Capvidia Expands Model-Based Definition (MBD) Interoperability with QIF-Enabled NX Software
Capvidia, a pioneer in Model-Based Definition (MBD) and digital interoperability, announces full integration support for the latest Siemens’ NX™ software release. This significant advancement enhances the enablement of Model-Based Characteristics (MBC) via the QIF standard, reinforcing the digital thread from design to quality and manufacturing across OEMs and their global supply chains.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609650970/en/
Siemens' NX and Capvidia's MBDVidia support True MBD workflows with support for bidirectional interoperability from design to manufacturing.
With this release, Siemens’ NX software becomes the first major CAD platform to natively support intelligent PMI ballooning and Model-Based Characteristics using QIF. As the only CAD-neutral standard designed for end-to-end digital metrology and quality workflows, this integration represents a groundbreaking development in the industry.
Capvidia’s flagship solution, MBDVidia, fully supports this advancement with bidirectional interoperability. Model data exported from NX via QIF can be validated, enriched, and returned, facilitating true closed-loop feedback between design, quality, and manufacturing.
“Capvidia has been instrumental in shaping QIF adoption across industries. With MBDVidia, we provide the trusted backbone for verifying and exchanging model-based data between CAD, CMM, and PLM systems,” said Tomasz Luniewski, CEO of Capvidia. “The integration between NX and MBDVidia is the first step of fully realizing the end-to-end automation and traceability from design to manufacturing.”
Key Benefits of the NX–MBDVidia Integration:
- Downstream Automation: MBDVidia automates inspection planning, First Article Inspection (FAI) reports, and metrology workflows using NX-generated QIF data—reducing manual rework and setup time.
- Upstream Intelligence: MBDVidia sends validated and enriched QIF data back into NX to improve product quality and enable design-for-inspection.
- Cross-CAD Interoperability: MBDVidia supports native MBD across Siemens’ NX, PTC Creo, SOLIDWORKS, and Autodesk Inventor—ensuring full compatibility across design, quality, and manufacturing systems.
By aligning with QIF and supporting model-based characteristics, Siemens’ and Capvidia jointly enable manufacturers to reduce errors, eliminate redundant effort, and accelerate their transition to the Model-Based Enterprise (MBE).
To learn more about how Capvidia is enabling model-based collaboration at scale, visit www.capvidia.com. To learn more about NX, visit https://plm.sw.siemens.com/en-US/nx/
About Capvidia
Capvidia is a global leader in Model-Based Definition (MBD) and Model-Based Enterprise (MBE) solutions, specializing in CAD translation, validation, and digital product definition. With a strong focus on interoperability and standards compliance, Capvidia empowers engineering and manufacturing organizations to improve data accuracy, streamline workflows, and drive digital transformation. Trusted by leading OEMs and suppliers worldwide, Capvidia continues to push the boundaries of MBD innovation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250609650970/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AwardFares Launches Intelligent New Alert System for Award Flight Availability5.8.2025 08:00:00 CEST | Press release
AwardFares, the leading search platform for award flights, today launched a major upgrade to its alert system, giving users smarter tools to discover and book award availability faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804412041/en/ AwardFares' Timeline view provides a clear, color-coded visualization of daily award seat availability across different cabin classes, helping users easily spot trends and opportunities for flights. The new system includes two powerful features: Flex Alerts and Live Alerts. Together, they provide both flexibility and precision, helping travelers maximize their points and miles like never before. Flex Alerts are designed for the flexible traveler. Instead of requiring an exact route and date, users can set broad criteria such as "any airport in the US to Europe for an entire month.” AwardFares' AI-powered system intelligently identifies matching availability, focusing not just on
Venture Global Calcasieu Pass Receives Uprate Approval from U.S. Department of Energy5.8.2025 02:02:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) received approval from the U.S. Department of Energy (DOE) for an uprate amendment to its Calcasieu Pass LNG project. The uprate approval increases Calcasieu Pass’ permitted peak liquefaction capacity from 12.0 million tonnes per annum (MTPA) to 12.4 MTPA. “Venture Global thanks its regulators, including DOE, for their efforts in prioritizing and streamlining approvals for critical energy infrastructure projects. These multibillion dollar investments will be key as the United States strengthens global energy security and increases energy trade with our partners around the world,” said Venture Global CEO Mike Sabel. Calcasieu Pass, Venture Global’s first project, reached first LNG production in 2022 and began commercial operations in April 2025. The company’s second facility, Plaquemines LNG, began LNG production in December 2024. Venture Global’s third project, CP2, received DOE export authorization and FERC approval in March 2025 and May 2025, re
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain4.8.2025 22:01:00 CEST | Press release
– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint –– Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo. VX-993 was generally safe and well tolerated. Most adverse events (AEs) were mild to moderate, and there were no serious adverse events (SAEs) related to VX-993. Based on these results, Vertex will not progress
TOURISE Announces Cross-Sector Advisory Board to Champion Bold New Platform Rewriting the Rules of Tourism4.8.2025 20:53:00 CEST | Press release
Leaders from World Travel & Tourism Council (WTTC), Global Sustainable Tourism Council, Amadeus, TikTok, Six Senses, Cirque du Soleil, Turismede Barcelona, Liberty International, Wagonlit Travel, Once Billion Happy, the Saudi Tourism Authority (STA), and the Riyadh School of Tourism and Hospitality at the helm of TOURISE Advisory Board Formation of the Advisory Board reinforces TOURISE’s dedication to driving cross-sector global collaboration Advisory Board shape TOURISE summit agenda, ensuring high-impact global issues such as equity, geographical representation and sectoral diversity are in spotlight TOURISE, the bold new global tourism platform, has announced the members of its cross-sector Advisory Board, a powerhouse of industry titans guiding TOURISE’s strategic direction and shaping the agenda of the inaugural global summit taking place in Riyadh from 11-13 November, 2025. TOURISE is where cross-sector convergence begins, a platform where leaders and visionaries debate, collabor
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe4.8.2025 20:38:00 CEST | Press release
Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA’s IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical’s mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804524652/en/ Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study Dr. Samin Sharma enrolled the first patient at New York’s Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom